Clinical Trials
33 trialsNCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05658640 2025-09-16
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05745714 2025-09-16
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05751044 2025-09-16
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT00410423 2025-04-30
Study of VELCADEĀ® With Mitoxantrone and Etoposide for Leukemias
Thomas Jefferson University
Phase 1/2 Completed
NCT00516828 2023-08-04
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT02464657 2021-10-07
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02305563 2021-09-16
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01656252 2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2 Terminated
NCT01289457 2020-02-24
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00968253 2019-02-27
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00655395 2019-01-28
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Viron Therapeutics Inc
Phase 1/2 Terminated
NCT00780143 2018-11-09
Clinical Study of Plitidepsin (AplidinĀ®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
PharmaMar
Phase 1/2 Terminated
NCT00542971 2018-08-23
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00541866 2018-01-09
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Sunesis Pharmaceuticals
Phase 1/2 Completed
NCT00609739 2017-12-28
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
Phase 1/2 Terminated
NCT00372619 2017-06-05
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 1/2 Completed
NCT00469859 2017-03-15
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Children's Oncology Group
Phase 1/2 Completed
NCT00014495 2016-01-22
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00472849 2013-11-26
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00028847 2013-09-17
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00003619 2013-06-26
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00002925 2012-11-30
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00002761 2012-11-19
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Columbia University
Phase 1/2 Withdrawn
NCT00005793 2012-09-25
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00480987 2012-08-07
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00569010 2012-08-01
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00838240 2012-07-20
AML-14A
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Unknown
NCT00027547 2011-11-30
Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00452374 2011-11-02
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00840684 2011-05-13
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00005802 2010-04-02
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Phase 1/2 Completed